RxDoctor Payments Data

Susan Harrison

Nurse Practitioner · Belleville, NJNPI 1942286117

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.3% of the total across 304 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,151, 3.9 times the $556 reported in 2021. Among nurse practitioner clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,430in general payments, 2019–2025

Across 304 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Daiichi Sankyo Inc.$489
  • AbbVie$478
  • Incyte Corporation$456
  • E.r. Squibb & Sons, L.L.C.$428
  • Johnson & Johnson$398
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$6,06294%
  • Education$3686%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,430 in reported general payments places this provider in the 95th percentile of 2,138 nurse practitioner providers in New Jersey.

See all nurse practitioner providers in New Jersey

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide49$1,148,160
RevlimidLenalidomide20$384,419
BrukinsaZanubrutinib25$369,961
LenvimaLenvatinib Mesylate12$289,088
ImbruvicaIbrutinib16$260,244
JakafiRuxolitinib Phosphate12$202,613
IbrancePalbociclib12$193,322
PromactaEltrombopag Olamine14$186,227
Lenalidomide14$182,143
NubeqaDarolutamide12$153,062
EliquisApixaban50$45,572
Abiraterone Acetate24$13,089
XareltoRivaroxaban11$10,279
Imatinib Mesylate28$6,700
Letrozole141$3,381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$428$1,148,16049 claims
Bristol Myers SquibbRevlimid$29$384,41920 claims
Beigene USA, Inc.Brukinsa$89$369,96125 claims
Eisai Inc.Lenvima$70$289,08812 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$74$260,24416 claims
PfizerIbrance, Eliquis$119$238,89462 claims
Incyte CorporationJakafi$456$202,61312 claims
NovartisPromacta$152$186,22714 claims
BayerNubeqa$179$153,06212 claims
Johnson & JohnsonXarelto$398$10,27911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,138 nurse practitioner providers in New Jersey.

Other nurse practitioner in Belleville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →